1. Home
  2. ZYBT vs GLUE Comparison

ZYBT vs GLUE Comparison

Compare ZYBT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYBT
  • GLUE
  • Stock Information
  • Founded
  • ZYBT 2004
  • GLUE 2019
  • Country
  • ZYBT China
  • GLUE United States
  • Employees
  • ZYBT N/A
  • GLUE N/A
  • Industry
  • ZYBT
  • GLUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZYBT
  • GLUE Health Care
  • Exchange
  • ZYBT NYSE
  • GLUE Nasdaq
  • Market Cap
  • ZYBT 340.3M
  • GLUE 276.2M
  • IPO Year
  • ZYBT 2025
  • GLUE 2021
  • Fundamental
  • Price
  • ZYBT $5.88
  • GLUE $4.57
  • Analyst Decision
  • ZYBT
  • GLUE Buy
  • Analyst Count
  • ZYBT 0
  • GLUE 3
  • Target Price
  • ZYBT N/A
  • GLUE $14.33
  • AVG Volume (30 Days)
  • ZYBT 449.3K
  • GLUE 452.3K
  • Earning Date
  • ZYBT 01-01-0001
  • GLUE 08-07-2025
  • Dividend Yield
  • ZYBT N/A
  • GLUE N/A
  • EPS Growth
  • ZYBT N/A
  • GLUE N/A
  • EPS
  • ZYBT 0.06
  • GLUE 0.08
  • Revenue
  • ZYBT $26,111,272.00
  • GLUE $159,487,000.00
  • Revenue This Year
  • ZYBT N/A
  • GLUE $49.02
  • Revenue Next Year
  • ZYBT N/A
  • GLUE N/A
  • P/E Ratio
  • ZYBT $108.13
  • GLUE $58.85
  • Revenue Growth
  • ZYBT N/A
  • GLUE 14889.38
  • 52 Week Low
  • ZYBT $3.50
  • GLUE $3.21
  • 52 Week High
  • ZYBT $14.30
  • GLUE $12.40
  • Technical
  • Relative Strength Index (RSI)
  • ZYBT N/A
  • GLUE 51.26
  • Support Level
  • ZYBT N/A
  • GLUE $4.47
  • Resistance Level
  • ZYBT N/A
  • GLUE $4.85
  • Average True Range (ATR)
  • ZYBT 0.00
  • GLUE 0.29
  • MACD
  • ZYBT 0.00
  • GLUE -0.01
  • Stochastic Oscillator
  • ZYBT 0.00
  • GLUE 32.58

About ZYBT ZHENGYE BIOTECHNOLOGY HLDG LTD

Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

Share on Social Networks: